<DOC>
	<DOCNO>NCT02688764</DOCNO>
	<brief_summary>This Phase 3 , Open-label , Randomised , Active-controlled , Parallel Group , Multicentre Study Investigate Safety Efficacy PA21 ( Velphoro® ) Calcium Acetate ( Phoslyra® ) Paediatric Adolescent CKD Patients Hyperphosphataemia . The aim Phase 3 clinical study demonstrate similar efficacy PA21 ( Velphoro ) paediatric adolescent patient CKD , provide safety dose information patient population . The Phoslyra ( comparator ) group provide information descriptive comparison PA21 commonly use calcium-based phosphate binder ( calcium acetate ) .</brief_summary>
	<brief_title>An Study Investigate Safety Efficacy PA21 ( Velphoro® ) Calcium Acetate ( Phoslyra® ) Paediatric Adolescent Chronic Kidney Disease ( CKD ) Patients With Hyperphosphataemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Calcium acetate</mesh_term>
	<criteria>1 . Subjects 0 &lt; 18 year time consent . 2 . Subjects hyperphosphataemia 3 . Subjects ≥1 year CKD Stages 45 define glomerular filtration rate &lt; 30 mL/min/1.73 m2 CKD Stage 5D receive adequate maintenance haemodialysis ( HD ) peritoneal dialysis ( PD ) least 2 month prior screen . 4 . Subjects &lt; 1 year must CKD . 5 . Appropriate write informed consent , appropriate/required assent , provide . 1 . Subjects hypercalcaemia screen 2 . Subjects intact parathyroid hormone ( iPTH ) level &gt; 700 pg/mL screening . 3 . Subjects PB naïve weigh &lt; 5 kg screening . Subjects receive stable dos PBs weigh &lt; 6 kg screen 4 . Subjects require feed tube size ≤6 FR ( French catheter scale ) . 5 . Subjects history major gastrointestinal surgery significant gastrointestinal disorder . 6 . Subjects hypocalcaemia ( serum total correct calcium &lt; 1.9 mmol/L ; &lt; 7.6 mg/dL ) screening . 7 . Subject pregnant ( e.g. , positive human chorionic gonadotropin test ) breast feeding . 8 . Subject significant medical condition ( )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>PA21</keyword>
	<keyword>phosphate binder</keyword>
</DOC>